drugset / Trial / NCT07112339

A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

NCT07112339

Phase 4 Recruiting 586 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.

Timeline

Start
2025-08-15
Primary completion
2026-08-04
Completion
2028-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin icodec Protein / enzyme biologic Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous
Comparator insulin detemir Protein / enzyme biologic Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous